Single-cell mtDNA heteroplasmy in colorectal cancer

João Almeida¹, Andrés Pérez-Figueroa^{1,2,3}, João M. Alves^{2,3}, Monica Valecha^{2,3}, Sonia Prado-López^{2,3}, Pilar Alvario^{2,3}, Jose Manuel Cameselle-Teijeiro^{4,5}, Debora Chantada⁶, Miguel M. Fonseca¹, David Posada^{2,3,7}

¹Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), University of Porto, Portugal.

²CINBIO, Universidade de Vigo, 36310 Vigo, Spain.

³Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO.

⁴Department of Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), Santiago de Compostela, Spain

⁵Medical Faculty, University of Santiago de Compostela, Santiago de Compostela, Spain

⁶Department of Pathology, Hospital Alvaro Cunqueiro, Vigo, Spain.

⁷Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, 36310 Vigo, Spain

Corresponding author: David Posada, dposada@uvigo.es

Abstract

Human mitochondria can be genetically distinct within the same individual, a phenomenon known as heteroplasmy. In cancer, this phenomenon seems exacerbated, and most mitochondrial mutations seem to be heteroplasmic. How this genetic variation is arranged within and among normal and tumor cells is not well understood. To address this question, here we sequenced single-cell mitochondrial genomes from multiple normal and tumoral locations in four colorectal cancer patients. Our results suggest that single cells, both normal and tumoral, can carry various mitochondrial haplotypes. Remarkably, this intra-cell heteroplasmy can arise before tumor development and be maintained afterward in specific tumoral cell subpopulations. At least in the colorectal patients studied here, the somatic mutations in the single-cells do not seem to have a prominent role in tumorigenesis.

Introduction

As each human cell contains hundreds or thousands of mitochondria (Stewart and Chinnery 2021), wild-type and mutant mtDNA can co-exist in a state called *heteroplasmy*. Heteroplasmy levels can change within a given cell due to different processes like relaxed replication, degradation, *de novo* mutation, intercellular transfer, and recombination (Stewart and Chinnery 2015; Johnston and Burgstaller 2019). As mitochondria are randomly distributed to daughter cells during cell division, the levels of heteroplasmy among cells can also fluctuate over time (Elson et al. 2001) and modulate the potential phenotypic penetrance of associated diseases, including cancer (Wallace and Chalkia 2013; McMahon and LaFramboise 2014; Stewart and Chinnery 2015; Stefano and Kream 2016; Hopkins et al. 2017; Stefano et al. 2017; Fendt et al. 2020). Potentially, the proportion of mutant mtDNA in a tissue may drift toward fixation and reach homoplasmy. However, in cancer, the vast majority of the tumoral mtDNA mutations (>85%) in tissue samples seem to be heteroplasmic, with variant allele frequencies (VAFs) lower than 0.6 (Yuan et al. 2020). How the overall mtDNA heteroplasmy is structured among and within cells is unknown. A given amount of mtDNA heteroplasmy can be explained by a population of cells carrying each a single but distinct mtDNA haplotype (*intercellular*

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

homoplasmy) or by a population of more or less similar cells carrying several mtDNA haplotypes each (*intracellular heteroplasmy*). In other words, we do not know whether single cells typically have one or multiple mtDNA haplotypes (He et al. 2010). Due to random drift and selection, within-cell homoplasmy is expected to take place in dividing cells eventually, but not necessarily in non-dividing cells (Pérez-Amado et al. 2021).

On the other hand, the number of mtDNA molecules per cell fluctuates among human tissues (D'Erchia et al. 2015). In many types of cancer, tumor cells have fewer copies of mtDNA than the normal cells (Tseng et al. 2006; McMahon and LaFramboise 2014; Reznik et al. 2016). Variation in the number of mtDNA copies can serve as a potential biomarker for cancer, where a higher risk was associated with copy number variation (Lan et al. 2008; Thyagarajan et al. 2013). However, how mtDNA copy number varies within and among cells has not yet been studied.

Finally, intratumor heterogeneity (ITH), particularly the spatial separation of somatic mutations within a tumor, is a determinant tumor characteristic in malignant growth, invasion, metastasis, and resistance acquisition (Bedard et al. 2013; Stanta and Bonin 2018). Nonetheless, the levels of mtDNA ITH across different samples of the same tissue have not been studied yet at the single-cell level.

This study leveraged tumor multiregional single-cell whole-genome data from four colorectal cancer patients to overview how mtDNA mutation frequency and copy number are distributed among and within cells and across geographical space.

Results

Single-cell mtDNA coverage heterogeneity

The average sequencing depth, or coverage, across the mitochondrial genome, was 998×, 574×, 236× and 881× for CRC01, CRC07, CRC08, and CRC12, respectively. The coverage distribution was heterogeneous, with a consistent overrepresentation of particular regions across patients (Table S1, Figure S1). The breadth of the coverage, i.e., the percentage of positions covered by at least one read, was 92-97%. Around 70% of the genomes were covered on average by at least 10 reads (only 57% for CRC08).

Single-cell mtDNA variants

We identified 3, 16, 23, and 20 mtDNA variants, primarily single nucleotide changes, in patients CRC01, CRC07, CRC08, and CRC12, respectively (Table S2). In CRC01, we found 3 germline variants. In CRC07, we identified 2 germline, 4 somatic, and 10 somatic/germline variants. In CRC08, we found 2 germline, 7 somatic, and 14 somatic/germline variants. Finally, in CRC12, we identified 13 germline and 7 somatic/germline variants. See Table S3 for a definition of the somatic, germline, and somatic/germline categories.

Within-cell mtDNA heteroplasmy

We found no heteroplasmic variants in CRC01 (Figure 1), but at least one in 60/105 cells (57.1%) in CRC07 (Figure 2), 35/52 (67.3%) in CRC08 (Figure 3), and 9/65 (13.8%) in CRC12 (Figure 4). In CRC07, we observed within-cell heteroplasmy (VAF between 0.1 and 0.9) in 13/16 (81.3%) variant sites, and among-cell heteroplasmy (i.e., VAF less than 0.1 in some cells and more than 0.9 in others) in 8/16 (50%) (Figure 2). At site 15149, a somatic tumor variant appears at high frequency in the tumoral bulk and in specific tumor cells sampled from the distal and middle regions while is absent from the healthy cells. At site 6220, multiple normal and tumor cells showed a somatic variant at a shallow frequency –except for a normal cell, which shows a very high VAF– that was not detected in the corresponding bulk samples. At site 13993, we see a similar pattern, with a few normal and tumor

cells showing a fixed somatic variant. At site 10704, a high-frequency variant was absent in some cells and fixed in others regardless of their normal/tumor status. At site 13966, we observed a similar situation, although in this case, the variant was fixed in both normal and tumoral bulk samples.

In CRC08, we observed within-cell heteroplasmy in 17/23 (73.9%) variants and among-cell heteroplasmy in 8/23 (34.8%) (Figure 3). At sites 64 and 664, the alternative allele only appears in tumoral cells sampled from the central region, reaching complete fixation at site 64. At site 15059, all normal cells and the tumor cells sampled from the central area are homoplasmic for the reference allele, while most tumor cells from the proximal and distal regions show a high VAF. In CRC12, we observed within-cell heteroplasmy in 6/20 (30%) variants and among-cell heteroplasmy in 3/20 (15%) (Figure 4). The variant at site 12308 was absent in some cells and fixed in others regardless of their normal/tumor status.

Figure 1. Single-cell mtDNA variant allele frequencies for CRC01. The plot depicts the mtDNA variant allele frequencies (VAFs) for two bulk samples (on top, one normal and one tumoral) and 46 single-cells at three variable sites in patient CRC01. VAF values vary from blue to red, representing the extremes 0 and 1, and grey indicates missing data (no reads at that site). The four rightmost columns indicate which rows represent bulk or single-cell samples, normal or tumoral tissue, different anatomical locations, and distinct cell types.

Figure 2. Single-cell mtDNA variant allele frequencies for CRC07. The plot depicts the mtDNA variant allele frequencies (VAFs) for two bulk samples (on top, one normal and one tumoral) and 105 single-cells at 16 variable sites in patient CRC07. VAF values vary from blue to red, representing the extremes 0 and 1, and grey indicates missing data (no reads at that site). The four rightmost columns indicate which rows represent bulk or single-cell samples, normal or tumoral tissue, different anatomical locations, and distinct cell types.

Figure 3. Single-cell mtDNA variant allele frequencies for CRC08. The plot depicts the mtDNA variant allele frequencies (VAFs) for two bulk samples (on top, one normal and one tumoral) and 52 single cells at 23 variable sites in patient CRC08. VAF values vary from blue to red, representing the extremes 0 and 1, and grey indicates missing data (no reads at that site). The four rightmost columns indicate which rows represent bulk or single-cell samples, normal or tumoral tissue, different anatomical locations, and distinct cell types.

Figure 4. Single-cell mtDNA variant allele frequencies for CRC12. The plot depicts the mtDNA variant allele frequencies (VAFs) for two bulk samples (on top, one normal and one tumoral) and 65 single cells at 20 variable sites in patient CRC12. VAF values vary from blue to red, representing the extremes 0 and 1, and grey indicates missing data (no reads at that site). The four rightmost columns indicate which rows represent bulk or single-cell samples, normal or tumoral tissue, different anatomical locations, and distinct cell types.

Functional impact of single-cell mtDNA variants

Heteroplasmic sites were significantly enriched in missense mutations in CRC07, stop gains in CRC08, and rRNA mutations in CRC12 (Table S4). The number of non-synonymous and synonymous mutations in normal and tumor cells was too small for a reliable estimation of the ratio of non-synonymous to synonymous rates (dN/dS) (Nei and Gojobori 1986). Non-synonymous variants did not have, overall, a higher VAF than synonymous variants in the tumors.

Single-cell mtDNA population structure

The F_{ST} statistic for cell differentiation was relatively high for CRC07, CRC08, and CRC12 (0.729, 0.667, and 0.878, respectively), but not for CRC01 (0.079). These F_{ST} values suggest that a larger fraction of the observed heteroplasmy results from differences among cells. Still, at the same time, there is a noticeable level of within-cell heteroplasmy, as we can appreciate in the VAF plots. The analysis of molecular variance (AMOVA) unveiled significant genetic differences among normal and tumor cell populations, among anatomical locations, and among cell types in CRC07 and among anatomical areas in CRC08 (Table 1). We could not run the AMOVA for patient CRC01 because of its low genetic variability.

Table 1. Analysis of Molecular Variance (AMOVA). P-values of the AMOVA for the Nei's genetic distances computed from the single-cell VAF values across all individual samples and for different hierarchical levels.

Group	CRC07	CRC08	CRC12
Tumor/Normal	0.000***	0.394	0.971
Location within Tumor/Normal	0.001***	0.000***	0.149
Cell type within Tumor/Normal	0.019*	0.055	0.535

* p-value ≤ 0.05 , ** p-value ≤ 0.01 , *** p-value ≤ 0.001

In addition, we found significant pairwise genetic differences in CRC07 between all tumoral locations (Table S5) and between two of the tumoral areas and the normal locations. We also found significant differences in CRC08 between the normal proximal location and all three tumoral locations and between the central tumor location and the other two tumor locations. In CRC12, only the distance between the distal and proximal tumor locations was significant. Besides, we observed significant pairwise genetic differences in CRC07 among every cell type, except among tumor stem 2 (TS2) and tumor non-stem cells (TNS) (Table S6). In CRC08, we found significant differences between several non-stem and stem cell types in normal and tumor tissues. Finally, in CRC12, we only observed significant differences between TS2 and normal stem 2 (NS2) cells.

We carried out principal component analyses to better characterize the mtDNA differences among the different groups of cells. The separation between specific tumoral and normal cells was not apparent in any of the patients (Figure S2), although in CRC08, the tumor cells are much more dispersed than the normal cells. When considering the geographical location, most cells overlap in the four patients (Figure S3). The same lack of specific patterns can be seen at the cell type level (Figure S4).

Single-cell mtDNA copy number variation

We estimated a statistically significant (p-value ≤ 0.05) higher number of mtDNA copies in tumor cells in patients CRC01 (16507 copies on average in tumor cells versus 2197 in normal cells), CRC07 (302 vs. 181), and CRC12 (534 vs. 258), but not in CRC08 (135 vs 167; p-value = 0.48) (Figure 5). In CRC01, we observed a significantly higher number of mtDNA copies in the large bowel's normal cells than in the duodenum. In CRC07, we detected significantly more mtDNA copies in normal and tumor cells in the distal region than in the proximal region.

Figure 5. Single-cell mtDNA copy number in normal and tumor cells. Copy number for some cells could not be calculated due to a lack of diploid regions (CRC01, n= 40; CRC07, n= 96; CRC08, n= 44; CRC12, n= 64).

Discussion

In this study, we have leveraged single-cell whole-genome sequencing data to study the levels of mtDNA heteroplasmy within and between cells in four CRC patients. To our knowledge, this is the first study addressing mtDNA heteroplasmy at the single-cell level in normal and cancer tissues.

We identified a limited number of somatic mtDNA variants, consistent with previous studies (Yuan et al. 2020). Still, our results indicate that a single (normal or tumoral) cell can carry multiple mtDNA haplotypes and that these levels of intra-cell heteroplasmy can change from patient to patient.

Notably, at least in patients CRC07 and CRC08, some sites are heteroplasmic both in normal and tumor cells, suggesting that the genetic bottleneck produced during transformation (i.e., we assume that all the tumor cells descend from a single, ancestral tumor cell) does not necessarily eliminate the intra-cell mtDNA variation present in the transformed cell. In other words, this suggests not only that many mtDNA mutations do pre-date cancer itself (Chinnery et al. 2002) but also that these mutations can be heteroplasmic within the original tumor cell.

In our data set, heteroplasmy is mainly a result of differences among cells than within cells, as expected in a population of dividing cells where the mitochondrial population is subject to drift and, potentially, selection. Still, intracell heteroplasmy does occur. We observed some changes in within-cell heteroplasmy among normal and tumor cell populations, among distinct anatomical locations, or different cell types in some patients. In the VAF plots, we could identify clear groups of cells with consistent allele frequency changes at specific sites. For example, we observed three sites in which a variant was absent in the normal cells but frequent in at least some tumor regions (T15149C in CRC07 and at C64T and G15059A in CRC08). Curiously, in CRC08, these two variants reached fixation (or almost fixation) in different regions of the same tumor. Still, these VAF changes

do not appear to have a clear functional relevance. Skonieczna et al. (2018) found several mtDNA variants in a cohort of 100 CRC patients that were heteroplasmic in the normal tissue but homoplasmic in the tumors. Still, we did not observe cases like this, perhaps because of our limited sample size.

We estimated a higher mtDNA copy number in the tumoral than in normal cells. Despite mitochondrial copy numbers varying wildly within and across cancers (Yuan et al. 2020), our numbers are consistent with the increased mtDNA copy number seen in several types of cancer (Tickoo et al. 2000; Lan et al. 2008; Shen et al. 2010; Thyagarajan et al. 2013).

In principle, mtDNA somatic mutations accumulate in a neutral, or nearly neutral, fashion (Ju et al. 2014; Yuan et al. 2020). In our single-cell datasets, non-synonymous variants did not reach a higher VAF than synonymous variants, suggesting in any case that the variants we detected are not associated with tumor development.

Methods

Sample collection

We obtained multiple tumoral and normal tissue samples from four colorectal cancer patients (Table S7). CRC01 samples were obtained during a warm autopsy, while the samples from the other patients were obtained from excess tumor tissue present in the colectomy specimens. All colorectal cancers were conventional adenocarcinomas (not otherwise specified), according to the criteria of the latest World Health Organization (WHO) digestive system tumors classification (Who Classification of Tumours Editorial Board 2019). Samples included in this study were provided by the Biobanks of the Health Research Institute of Santiago (PT13/0010/0068) and Galicia Sur Health Research Institute (B.0000802), both integrated into the Spanish National Biobank Network. Samples were processed following standard operating procedures with the approval of the Ethical and Scientific Committees (CAEI Galicia 2014/015). Written informed consents were provided by the patients or by their families.

Tumor disaggregation and sorting

We froze the tissue samples in liquid nitrogen, placed them in dry ice, and transported them to the laboratory. Next, we minced the samples into pieces of 1 mm³ with a scalpel and digested by incubation in Accutase (LINUS) for 1 h at 37 °C. After that, we filtered the cell suspension with a 70 µm cell strainer (FALCON) and assessed cell viability with Tripan Blue (Gibco). When the percentage of dead cells exceeded 30%, we did a Ficoll-Paque density gradient centrifugation to get rid of dead cells before sorting. We washed the cell pellets twice, suspended them in ice-cold phosphate-buffered saline (PBS), and stained them for 30 min with the following monoclonal antibodies: Anti-EpCAM (EBA1) (FITC)-conjugated, Anti-CD44 (APC)-conjugated, Anti-CD166 (PE)-conjugated, Anti-Lgr5 (VB 421)-conjugated. All antibodies were purchased from BD Biosciences. Following three successive washes in the PBS buffer, we added DRAQ5 and 7AAD dyes to select nucleated cells and exclude non-viable ones. We carried out flow cytometry analyses, and sorting of EpCAM+/CD44-/CD166-/Lgr5+ (tumoral stem 1 [TS1] and normal stem 1 [NS1] cells); EpCAM+/CD44+/CD166-/Lgr5- (tumoral stem 2 [TS2] and normal stem 2 [NS2]) and EpCAM+/CD44-/CD166-/Lgr5- (tumoral non-stem [TNS] and normal non-stem [NNS]) cell populations with a FACS ARIA III (BD Biosciences), and analyzed the data with the BD FACSDiva and Miltenyi Biotec Flowlogic software. In total, we selected 268 cells for further analysis (46 for CRC01, 105 for CRC07, 52 for CRC08 and 65 for CRC12), from those, 133 (18 TS1 + 59 TNS + 56 TS2) were normal (healthy) and 135 (22 TS1 + 66 TNS + 47 TS) were tumor cells (Table S7).

Whole-genome single-cell and bulk sequencing

Single-cell whole genome amplification

To obtain enough DNA for sequencing from the individual cells, we carried out single-cell whole genome amplification (scWGA) with the Ampli1 Kit from Silicon Biosystems. To minimize potential contamination, we worked under a Biological Safety Cabinet, UV-irradiated all the plastic materials employed, and used a dedicated set of pipettes. In addition to patient cells, we included a positive (10 ng/μl REPLIg human control kit, QIAGEN) and negative (DNase/RNase free water) control in the amplification process. Next, we assessed the quality of the amplified DNA with the Ampli1 QC Kit and selected the positive samples for the 4 PCR DNA fragments. Then, we used the Ampli1 ReAmp/ds kit on the selected samples to increase the total double-stranded DNA. Later, we removed the kit adaptors adding 5 μl of NE Buffer 4 10X (New England Biolabs), 1 μl of MseI 50U/μl (New England Biolabs), and 19 μl of nuclease-free water to every 25 μl of a sample. We introduced the resulting mix in a thermocycler. Next, we applied a program consisting of a step of 37°C for 3 h, followed by 20 minutes at 65°C for enzyme inactivation. Then, we purified the Ampli1 products using 1.8X AMPure XP beads (Agencourt, Beckman Coulter). Later, we measured DNA yield, integrity, and amplicon size distribution with a Qubit 3.0 fluorometer (ThermoFisher Scientific) and a 2200 TapeStation platform with the D5000 ScreenTape assay (Agilent Technologies).

Bulk genomic DNA (gDNA) isolation

We isolated the gDNA from the bulk samples using the QIAamp DNA Mini kit (QIAGEN) following the fabricant recommendations. Next, We estimated the yield and DNA integrity as described for the single cells above but using the Genomic DNA Screentape Assay instead.

Library construction and next-generation sequencing

We sent all samples to the Spanish National Center for Genomic Analysis (CNAG), where bulk and single-cell whole-genome sequencing libraries were built using the KAPA (Kapa Biosystems) library preparation kit with some modifications. Bulk and single-cell libraries were sequenced at ~39X (bulk) and ~6X (single cells) in an Illumina NovaSeq 6000 platform.

Mitochondrial variant calling

To avoid the detection of mtDNA mutations caused by pseudogenes or homologous sequences in nuclear DNA (NUMTs), we aligned the reads to both nuclear and mitochondrial reference genomes, treating NUMTs and mitochondrial specific mutations equally, and thus, artificially producing a high coverage on these nuclear positions while creating a deficit in the mtDNA ones. This method, which trades less interference of NUMTs in mtDNA for lack of detection power for those positions in the mitogenome, has already been used in mtDNA variant calling pipelines (Guo et al. 2013). We mapped the reads to the Revised Cambridge Reference Sequence (rCRS) with SAMtools (Li et al. 2009) to get the first set of reads ready for calling input.

We converted back mtDNA reads mapped to rCRS and unmapped reads into FASTQ, following existing pipelines (Ding et al. 2015), and remapped them to a “shifted” rCRS, for consideration on the circularity of the mitochondrial genome (mt-genome). This procedure avoids unaligned and discarded reads on the extremities of the reference resulting from the artificial breakpoint of the mt-genome on the replication control region, defining the “start” at position 1 and “end” at position 16,569. In this double-alignment method (Ding et al. 2015), the “shifted” reference is created by switching the positions of, roughly, the first and second half of the rCRS so that positions 8001–16569 appear first, followed by positions 1–8000.

We applied quality control filters to avoid calling errors by selecting reads with a base quality score ≥ 20 , median depth ≥ 100 per individual, raw depth ≥ 40 , and depth after base quality score filter ≥ 10 , MAF $\geq 4\%$, as in Ding et al. (2015). For variant calling, we used Mutect2 on multi-sample mode

(Cibulskis et al. 2013) and with option --max-mnp-distance 0. The resulting variants were filtered with FilterMutectCalls. We performed the variant calling using all the bulk and single-cell samples together. We used the reads mapped to rCRS to call the variants for coordinates 4,000–12,000 and reads mapped to the “shifted” rCRS to call for coordinates 0–4,000 and 12,000–16,000. Then, we merged the two sets of called variants. Finally, we removed multiallelic variants, read depth 1, and variants with more than 20% missing data.

Estimation of the mtDNA copy number

We used fastMitoCalc (Ding et al. 2015; Qian et al. 2017) to estimate the mtDNA copy number as the depth ratio between mtDNA and nuclear DNA:

$$\text{mtDNA copy number} = \frac{\text{average number of mtDNA reads}}{\text{average number of nuclear DNA reads}} \times P$$

where P is the ploidy. This procedure assumes that regions of the genome of equal ploidy have the same depth (Guo et al. 2013; Samuels et al. 2013; Zhao et al. 2013; Cai et al. 2015; D’Erchia et al. 2015; Ding et al. 2015; Reznik et al. 2016; Zhang et al. 2017). For normal diploid cells, P is 2; however, cancer cells can exhibit large-scale genomic amplifications and deletions, altering their ploidy (Reznik et al. 2016). Therefore, we calculated the mtDNA copy number using only diploid nuclear regions (Cai et al. 2015; Zhang et al. 2017). We called single-cell copy-number variants (CNVs) with Ginkgo (Garvin et al. 2015) to identify these regions using variable-length bins of around 500 kb. After binning, data for each cell was normalized and segmented using default parameters.

Identification of within-cell heteroplasmy

We calculated the variant allele frequency (VAF) by dividing the allelic depth of the alternative allele by the total read depth. We classified as somatic those variants present in at least one single (normal or tumor) cell and absent or not fixed in the normal bulk, as germline those variants fixed in the normal bulk. Variants fixed in the normal bulk and present in at least one single (normal or tumoral) cell but not fixed were classified as germline and somatic. We consider a variant to be heteroplasmic for a given cell if its VAF was between 0.1 and 0.9. Otherwise we classified it as homoplasmic ($0.1 > \text{VAF} > 0.9$).

Population genetic structure

To quantify the structuration of heteroplasmy within and among cells, we computed the haploid equivalent of the F_{ST} statistic (Wright 1951), whose values go from 0 to 1. An F_{ST} of 0 will indicate that all heteroplasmy occurs because of differences among cells. A value of 1 will suggest that all heteroplasmy occurs because of differences within cells.

In addition, we used Nei’s (Nei 1972) distances from the VAFs with an in-house R script (<https://github.com/anpefi/sc-mtDNA>) to describe the mitochondrial population structure at the single-cell level. We carried out an analysis of molecular variance (AMOVA) (Excoffier et al. 1992) using the R package *pegas* (Paradis 2010) across different hierarchical levels: tumor vs. normal, location within tumor/normal, and cell type within tumor/normal. Additionally, a pairwise AMOVA, using the same method as the hierarchical AMOVA, was applied to the different groups at the location per tissue and cell type per tissue level. To evaluate the null hypothesis of no population structure, we used permutation tests with 10,000 replicates.

Functional analyses

To look for differences between the functional characterization of tumor and normal cells, we looked for alternatives to “typically normal allele” homoplasmic variants. We identified these “typically

normal allele” homoplasmic variants as the variants that differ from those considered as individually fixed in normal cells and distributed them into functional groups: synonymous, missense, or stop gain, for protein-coding, and intergenic or rRNA for non-protein-coding. We annotated and prioritized the variants using Ensemble’s Variant Effect Predictor (VEP) (McLaren et al. 2016). In addition, we annotated each variant using the online SNV query of MITOMASTER (Brandon et al. 2009).

Data availability

Data and scripts are available at <https://github.com/anpefi/sc-mtDNA>.

Acknowledgments

This work was supported by project No. 32030 awarded to M.F., co-financed by COMPETE 2020, Portugal 2020 and the EU through the ERDF, and by FCT (PTDC/BIA-EVL/32030/2017) through national funds, and by the European Research Council (ERC-617457-PHYLOCANCER awarded to D.P.) and Spanish Ministry of Science, Innovation, and Universities - MCIU (PID2019-106247GB-I00 awarded to D.P.). J.M.C.-T. is supported by grant no. ISCIII-PI19/01316 from Instituto de Salud Carlos III, State Research Agency and Ministry of Science and Innovation (Spain), with the participation of the European FEDER fund. We want to thank Sara Rocha for her helpful comments on this work.

References

- Bedard PL, Hansen AR, Ratain MJ, Siu LL. 2013. Tumour heterogeneity in the clinic. *Nature* 501:355–364.
- Brandon MC, Ruiz-Pesini E, Mishmar D, Procaccio V, Lott MT, Nguyen KC, Spolim S, Patil U, Baldi P, Wallace DC. 2009. MITOMASTER: a bioinformatics tool for the analysis of mitochondrial DNA sequences. *Hum. Mutat.* 30:1–6.
- Cai N, Li Y, Chang S, Liang J, Lin C, Zhang X, Liang L, Hu J, Chan W, Kendler KS, et al. 2015. Genetic Control over mtDNA and Its Relationship to Major Depressive Disorder. *Curr. Biol.* 25:3170–3177.
- Chinnery PF, Samuels DC, Elson J, Turnbull DM. 2002. Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism? *Lancet* 360:1323–1325.
- Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. 2013. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* 31:213–219.
- D’Erchia AM, Atlante A, Gadaleta G, Pavesi G, Chiara M, De Virgilio C, Manzari C, Mastropasqua F, Prazzoli GM, Picardi E, et al. 2015. Tissue-specific mtDNA abundance from exome data and its correlation with mitochondrial transcription, mass and respiratory activity. *Mitochondrion* 20:13–21.
- Ding J, Sidore C, Butler TJ, Wing MK, Qian Y, Meirelles O, Busonero F, Tsoi LC, Maschio A, Angius A, et al. 2015. Assessing Mitochondrial DNA Variation and Copy Number in Lymphocytes of ~2,000

- Sardinians Using Tailored Sequencing Analysis Tools. *PLoS Genet.* 11:1–18.
- Elson JL, Samuels DC, Turnbull DM, Chinnery PF. 2001. Random intracellular drift explains the clonal expansion of mitochondrial DNA mutations with age. *Am. J. Hum. Genet.* 68:802–806.
- Excoffier L, Smouse PE, Quattro JM. 1992. Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. *Genetics* 131:479–491.
- Fendt L, Fazzini F, Weissensteiner H, Bruckmoser E, Schönherr S, Schäfer G, Losso JL, Streiter GA, Lamina C, Rasse M, et al. 2020. Profiling of Mitochondrial DNA Heteroplasmy in a Prospective Oral Squamous Cell Carcinoma Study. *Cancers* [Internet] 12. Available from: <http://dx.doi.org/10.3390/cancers12071933>
- Garvin T, Aboukhalil R, Kendall J, Baslan T, Atwal GS, Hicks J, Wigler M, Schatz MC. 2015. Interactive analysis and assessment of single-cell copy-number variations. *Nat. Methods* 12:1058–1060.
- Guo Y, Li J, Li CI, Shyr Y, Samuels DC. 2013. MitoSeek: extracting mitochondria information and performing high-throughput mitochondria sequencing analysis. *Bioinformatics* 29:1210–1211.
- He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. 2010. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. *Nature* 464:610–614.
- Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua MLK, et al. 2017. Mitochondrial mutations drive prostate cancer aggression. *Nat. Commun.* 8:656.
- Johnston IG, Burgstaller JP. 2019. Evolving mtDNA populations within cells. *Biochem. Soc. Trans.* 47:1367–1382.
- Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A, et al. 2014. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. *Elife* [Internet] 3. Available from: <http://dx.doi.org/10.7554/eLife.02935>
- Lan Q, Lim U, Liu CS, Weinstein SJ, Chanock S, Bonner MR, Virtamo J, Albanes D, Rothman N. 2008. A prospective study of mitochondrial DNA copy number and risk of non-Hodgkin lymphoma. *Blood* 112:4247–4249.
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25:2078–2079.
- McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, Flicek P, Cunningham F. 2016. The Ensembl Variant Effect Predictor. *Genome Biol.* 17:122.
- McMahon S, LaFramboise T. 2014. Mutational patterns in the breast cancer mitochondrial genome, with clinical correlates. *Carcinogenesis* 35:1046–1054.
- Nei M. 1972. Genetic distance between populations. *Am. Nat.* [Internet]. Available from: <https://www.journals.uchicago.edu/doi/abs/10.1086/282771>
- Nei M, Gojobori T. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. *Mol. Biol. Evol.* 3:418–426.

- Paradis E. 2010. pegas: an R package for population genetics with an integrated–modular approach. *Bioinformatics* 26:419–420.
- Pérez-Amado CJ, Bazan-Cordoba A, Hidalgo-Miranda A, Jiménez-Morales S. 2021. Mitochondrial Heteroplasmy Shifting as a Potential Biomarker of Cancer Progression. *Int. J. Mol. Sci.* [Internet] 22. Available from: <http://dx.doi.org/10.3390/ijms22147369>
- Qian Y, Butler TJ, Opsahl-Ong K, Giroux NS, Sidore C, Nagaraja R, Cucca F, Ferrucci L, Abecasis GR, Schlessinger D, et al. 2017. fastMitoCalc: An ultra-fast program to estimate mitochondrial DNA copy number from whole-genome sequences. *Bioinformatics* 33:1399–1401.
- Reznik E, Miller ML, Şenbabaoğlu Y, Riaz N, Sarungbam J, Tickoo SK, Al-Ahmadie HA, Lee W, Seshan VE, Hakimi AA, et al. 2016. Mitochondrial DNA copy number variation across human cancers. *Elife* 5:1–20.
- Samuels DC, Han L, Li J, Quangu S, Clark TA, Shyr Y, Guo Y. 2013. Finding the lost treasures in exome sequencing data. *Trends Genet.* 29:593–599.
- Shen J, Platek M, Mahasneh A, Ambrosone CB, Zhao H. 2010. Mitochondrial copy number and risk of breast cancer: A pilot study. *Mitochondrion* 10:62–68.
- Skonieczna K, Malyarchuk B, Jawieñ A, Marszałek A, Banaszkiwicz Z, Jarmocik P, Grzybowski T. 2018. Mitogenomic differences between the normal and tumor cells of colorectal cancer patients. *Hum. Mutat.* 39:691–701.
- Stanta G, Bonin S. 2018. Overview on Clinical Relevance of Intra-Tumor Heterogeneity. *Front. Med.* 5:85.
- Stefano GB, Bjenning C, Wang F, Wang N, Kream RM. 2017. Mitochondrial Heteroplasmy BT - Mitochondrial Dynamics in Cardiovascular Medicine. In: Santulli G, editor. Cham: Springer International Publishing. p. 577–594.
- Stefano GB, Kream RM. 2016. Mitochondrial DNA heteroplasmy in human health and disease (Review). *Biomedical Reports* 4:259–262.
- Stewart JB, Chinnery PF. 2015. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. *Nat. Rev. Genet.* 16:530–542.
- Stewart JB, Chinnery PF. 2021. Extreme heterogeneity of human mitochondrial DNA from organelles to populations. *Nat. Rev. Genet.* 22:106–118.
- Thyagarajan B, Wang R, Nelson H, Barcelo H, Koh WP, Yuan JM. 2013. Mitochondrial DNA Copy Number Is Associated with Breast Cancer Risk. *PLoS One* [Internet] 8. Available from: <http://dx.doi.org/10.1371/journal.pone.0065968>
- Tickoo SK, Lee MW, Eble JN, Amin M, Christopherson T, Zarbo RJ, Amin MB. 2000. Ultrastructural Observations on Mitochondria and Microvesicles in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Eosinophilic Variant of Conventional (Clear Cell) Renal Cell Carcinoma. *Am. J. Surg. Pathol.* [Internet] 24. Available from: https://journals.lww.com/ajsp/Fulltext/2000/09000/Ultrastructural_Observations_on_Mitochondria_and.8.aspx
- Tseng L-M, Yin P-H, Chi C-W, Hsu C-Y, Wu C-W, Lee L-M, Wei Y-H, Lee H-C. 2006. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. *Genes Chromosomes Cancer*

45:629–638.

Wallace DC, Chalkia D. 2013. Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. *Cold Spring Harb. Perspect. Biol.* 5:1–47.

Who Classification of Tumours Editorial Board. 2019. WHO Classification of Tumours: Digestive System Tumours (WHO Classification of Tumours, Vol. 1). (Bosman F, Carneiro F, Hruban R, Theise N, editors.). Lyon: World Health Organization

Wright S. 1951. The genetical structure of populations. *Ann. Eugen.* 15:323–354.

Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, et al. 2020. Comprehensive molecular characterization of mitochondrial genomes in human cancers. *Nat. Genet.* 52:342–352.

Zhang P, Lehmann BD, Samuels DC, Zhao S, Zhao YY, Shyr Y, Guo Y. 2017. Estimating relative mitochondrial DNA copy number using high throughput sequencing data. *Genomics* 109:457–462.

Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, Abel PW, Tu Y. 2013. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. *Oncogene* 32:4814–4824.

Supplementary Material

Table S1. Mean individual mtDNA sequence coverage for each gene. Coverage percentage of each mitochondrial gene with at least 1, 10, and 100 reads across each individual. The bottom line presents the mean value of coverage for the overall mitogenome that expresses genes.

Region	Type	Start	End	Mean coverage (%)											
				CRC01			CRC07			CRC08			CRC12		
				1x	10x	100x	1x	10x	100x	1x	10x	100x	1x	10x	100x
TF	tRNA	577	647	100.0	100.0	87.0	100.0	100.0	100.0	100.0	98.8	74.4	100.0	100.0	98.5
RNR1	rRNA	648	1601	88.9	62.7	32.0	91.0	64.2	27.6	80.6	46.1	15.8	86.5	59.3	33.0
TV	tRNA	1602	1670	76.9	37.8	6.7	76.3	25.5	1.3	64.5	16.4	0.3	75.1	34.6	3.0
RNR2	rRNA	1671	3229	84.6	53.8	16.3	85.6	54.1	4.4	74.5	32.6	0.6	83.5	58.4	6.4
TL1	tRNA	3230	3304	81.6	40.8	13.1	87.3	40.6	8.9	59.6	13.9	3.5	71.7	32.3	8.4
ND1	coding	3307	4262	100.0	100.0	94.9	100.0	100.0	99.4	98.1	97.9	81.9	100.0	100.0	98.7
TI	tRNA	4263	4331	100.0	92.2	71.2	100.0	95.4	76.5	97.6	83.7	55.0	99.9	94.0	72.0
TQ	tRNA	4329	4400	100.0	85.1	30.6	100.0	91.0	22.8	98.1	56.4	1.9	100.0	86.8	15.4
TM	tRNA	4402	4469	100.0	83.1	28.9	100.0	89.9	21.7	98.1	55.1	1.9	100.0	85.3	15.2
ND2	coding	4470	5511	93.9	68.2	23.9	95.4	75.2	14.2	87.4	48.4	2.5	94.7	71.7	19.4
TW	tRNA	5512	5579	71.4	37.1	6.9	79.3	32.4	2.5	52.6	14.0	0.3	64.1	25.0	3.0
TA	tRNA	5587	5655	48.2	19.4	0.0	58.5	12.0	0.0	29.0	2.6	0.0	47.2	11.5	1.4
TN	tRNA	5657	5729	68.3	53.4	37.7	78.0	56.6	45.3	61.3	48.0	34.4	73.9	55.8	44.0
TC	tRNA	5761	5826	100.0	93.5	78.1	100.0	100.0	96.7	98.1	94.1	74.7	100.0	100.0	93.4
TY	tRNA	5826	5891	99.2	88.4	60.1	100.0	100.0	92.0	96.6	89.8	62.5	100.0	100.0	91.3
CO1	coding	5904	7445	99.0	89.4	64.9	100.0	99.2	85.2	99.0	89.3	62.8	100.0	99.0	82.3
TS1	tRNA	7446	7514	100.0	50.6	16.7	100.0	94.3	12.3	97.9	44.4	0.2	100.0	87.6	13.9
TD	tRNA	7518	7585	90.3	37.3	8.1	95.0	66.9	7.5	78.9	25.6	0.6	89.8	56.7	5.4
CO2	coding	7586	8269	97.1	88.4	78.8	98.1	88.7	76.1	95.8	80.3	67.8	96.9	87.2	75.2
TK	tRNA	8295	8364	64.3	27.6	5.8	79.5	28.5	3.5	51.5	8.2	0.0	66.4	21.4	3.1
ATP8	coding	8366	8572	94.6	76.3	56.0	97.2	78.4	57.9	90.2	61.4	36.4	95.0	74.5	56.5
ATP6	coding	8527	9207	97.8	80.8	51.2	98.8	84.1	47.3	93.1	64.8	30.8	95.8	77.9	46.0
CO3	coding	9207	9990	100.0	100.0	99.6	100.0	100.0	100.0	100.0	100.0	94.7	100.0	100.0	98.4
TG	tRNA	9991	10058	86.4	61.4	40.6	92.8	59.2	40.5	74.7	44.3	36.2	87.8	51.7	39.1
ND3	coding	10059	10404	94.1	77.0	27.6	96.4	79.2	17.8	87.8	61.6	4.3	94.9	77.9	39.1
TR	tRNA	10405	10469	82.4	57.3	28.6	90.1	58.1	36.7	71.6	38.9	16.4	86.8	54.7	35.2
ND4L	coding	10470	10766	100.0	98.5	66.2	100.0	100.0	97.1	99.3	89.2	48.8	100.0	100.0	95.7
ND4	coding	10760	12137	99.4	90.8	58.5	99.4	91.1	56.9	97.9	76.7	35.1	99.7	93.5	67.3
TH	tRNA	12138	12206	97.1	53.1	20.5	98.4	53.6	6.3	88.8	21.3	0.0	95.3	46.3	3.1
TS2	tRNA	12207	12265	97.6	54.8	21.7	97.9	52.1	6.7	89.0	20.9	0.0	93.8	42.0	3.1
TL2	tRNA	12266	12336	99.8	68.8	26.2	98.9	84.9	14.8	95.6	56.5	1.7	99.6	81.4	14.4
ND5	coding	12337	14148	99.5	90.4	62.3	99.8	94.4	65.6	97.8	76.8	44.8	99.6	95.2	68.7
ND6	coding	14149	14673	98.7	76.7	35.3	99.6	89.6	22.0	97.3	51.9	1.9	99.3	89.0	32.9
TE	tRNA	14674	14742	100.0	88.6	39.5	100.0	97.8	21.7	99.9	67.6	1.9	100.0	95.4	38.1
CYB	coding	14747	15887	99.0	96.3	89.0	99.5	97.1	91.2	97.2	91.4	78.6	98.8	95.6	89.8
TT	tRNA	15888	15953	100.0	100.0	92.3	100.0	100.0	99.0	100.0	99.1	75.5	100.0	100.0	98.0
TP	tRNA	15956	16023	91.7	65.3	36.0	96.2	64.2	37.5	79.0	44.0	19.1	92.0	61.4	37.2
CR	non-coding	16024	576	97.9	81.9	44.9	98.0	86.0	49.8	93.7	64.9	22.8	98.5	87.1	55.1
Mean value across genes				92.1	71.8	43.6	94.4	75.9	43.9	86.1	57.3	28.7	91.7	73.4	44.8

Table S2. Single-cell mtDNA variants. Var. type: variant type (see Table S3): G = Germline, S = Somatic, S/G = Somatic/Germline. Tissue Som.: tissue where the somatic variant appears N =Normal, T = Tumoral, N/T = Normal and Tumoral. Somatic variants are highlighted in bold.

Patient	Region	Position	Change	Var. Type	Tissue Som.	Annotation	Heteroplasmy
CRC01	RNR1	750	A>G	G	--	rRNA	No
	ND1	3666	G>A	G	--	ND1:G120G	No
	CYB	15326	A>G	G	--	CYB:T194A	No
CRC07	CR	73	A>G	S/G	N	non-coding	Yes
	RNR1	750	A>G	G	--	rRNA	No
	CO1	6220	CT>C	S	N/T	frameshift	Yes
	CO1	6221	T>C	S/G	N/T	CO1:P106P	Yes
	CO1	6371	C>T	S/G	N/T	CO1:S156S	Yes
	CO1	7028	C>T	S/G	N/T	CO1:A375A	Yes
	ATP6	8705	T>C	S/G	N	ATP6:M60T	Yes
	ND4L	10704	G>A	S	N/T	ND4L:V79I	Yes
	ND4	11719	G>A	S/G	N/T	ND4:G320G	Yes
	ND5	12705	C>T	G	--	ND5:I123I	No
	ND5	13966	A>G	S/G	N/T	ND5:T544A	Yes
	ND5	13993	C > 73bp*	S	N/T		Yes
	CYB	15149	T>C	S	T	CYB:W135R	Yes
	CYB	15326	A>G	S/G	N	CYB:T194A	Yes
	CYB	15804	T>C	S/G	N	CYB:V353A	Yes
	CR	16519	T>C	S/G	N	non-coding	Yes
CRC08	CR	64	C>T	S	T	non-coding	Yes
	CR	73	A>G	S/G	N	non-coding	Yes
	CR	494	C>T	S/G	N	non-coding	Yes
	RNR1	650	T>C	S/G	N/T	rRNA	Yes
	RNR1	664	G>A	S	T	rRNA	Yes
	RNR1	750	A>G	G	--	rRNA	No
	RNR1	813	A>G	S/G	N/T	rRNA	Yes
	ND1	3483	G>A	S/G	N/T	ND1:E59E	Yes
	NC5	5892	T>TC	S	N/T	non-coding	Yes
	NC5	5894	A>C	S	N/T	non-coding	Yes
	CO1	7028	C>T	S/G	T	CO1:A375A	Yes
	CO2	7933	A>G	S/G	T	CO2:L116L	Yes
	ATP6	8701	A>G	G	--	ATP6:T59A	No
	CO3	9299	A>G	S	T	CO3:L31L	Yes
	CO3	9540	T>C	S/G	N/T	CO3:L112L	Yes
	CO3	9941	A>G	S/G	N/T	CO3:V245V	Yes
	ND4	11719	G>A	S/G	N/T	ND4:G320G	Yes
	ND5	12705	C>T	S/G	T	ND5:I123I	Yes
	ND5	12727	T>C	S	T	ND5:L131L	No
	ND5	13368	G>A	S/G	N/T	ND5:G344G	Yes
	CYB	15059	G>A	S	T	CYB:G105TERM	Yes
	CYB	15758	A>G	S/G	N/T	CYB:I338V	Yes
	TT	15928	G>A	S/G	T	tRNA	Yes

CRC12	CR	73	A>G	S/G	N	non-coding	Yes
	CR	497	C>T	G	--	non-coding	No
	RNR1	750	A>G	G	--	rRNA	No
	RNR2	1811	A>G	G	--	rRNA	No
	ND1	3398	T>C	G	--	ND1:M31T	No
	ND1	3480	A>G	G	--	ND1:K58K	No
	CO1	7028	C>T	G	--	CO1:A375A	No
	CO3	9698	T>C	G	--	CO3:L164L	No
	ND4L	10550	A>G	S/G	N	ND4L:M27M	Yes
	ND4	11299	T>C	G	--	ND4:T180T	No
	ND4	11467	A>G	G	--	ND4:L236L	No
	ND4	11719	G>A	S/G	N/T	ND4:G320G	Yes
	TL2	12308	A>G	S/G	N/T	tRNA	Yes
	ND6	14167	C>T	G	--	ND6:E169E	No
	CYB	14798	T>C	S/G	T	CYB:F18L	Yes
	CYB	15326	A>G	G	--	CYB:T194A	No
	CR	16192	C>T	G	--	non-coding	No
	CR	16224	T>C	S/G	N/T	non-coding	Yes
	CR	16311	T>C	G	--	non-coding	No
	CR	16519	T>C	S/G	N/T	non-coding	Yes

* indel 73 bp: C > CCATTTGATTCCATTGATGTTGATTCCATTGATTCCATTATATGATGATTCCATGCAATTCATTAGATGA

Table S3. Classification of variants as somatic, germline, and somatic/germline.

Type	Tissue	Normal bulk	Tumor bulk	Normal single-cell	Tumor single-cell
Somatic	Tumor	absent	absent or present	absent	at least 1 cell
Somatic	Normal	not fixed	absent	at least 1 cell	absent
Somatic	Tumor and Normal	not fixed	absent or present	at least 1 cell	at least 1 cell
Germline	Tumor and Normal	fixed	fixed	fixed	fixed
Somatic / Germline	Tumor	fixed	absent or present	fixed	at least 1 cell but not fixed
Somatic / Germline	Normal	fixed	fixed	at least 1 cell but not fixed	fixed
Somatic / Germline	Tumor and Normal	fixed	absent or present	at least 1 cell but not fixed	at least 1 cell but not fixed

Table S4. Functional impact of single-cell mtDNA variants.

Patient ID	Site	Region	Consequence	Heteroplasmy
CRC08	64	CR	Intergenic	Yes
CRC07	73	CR	Intergenic	Yes
CRC08				Yes
CRC12				Yes
CRC08	494	CR	Intergenic	Yes
CRC12	497	CR	Intergenic	No
CRC08	650	RNR1	Non-coding	Yes
CRC08	664	RNR1	Non-coding	Yes
CRC01	750	RNR1	Non-coding	No
CRC07				No
CRC08				No
CRC12				No
CRC08	813	RNR1	Non-coding	Yes
CRC12	1811	RNR2	Non-coding	No
CRC12	3398	ND1	Missense	No
CRC12	3480	ND1	Synonymous	No
CRC08	3483	ND1	Synonymous	Yes
CRC01	3666	ND1	Synonymous	No
CRC08	5892	NC5	Non-coding	Yes
CRC08	5894	NC5	Intergenic	Yes
CRC07	6220	CO1	Frameshift	Yes
CRC07	6221	CO1	Synonymous	Yes
CRC07	6371	CO1	Synonymous	Yes
CRC07	7028	CO1	Synonymous	Yes
CRC08				Yes
CRC12				No
CRC08	7933	CO2	Synonymous	Yes
CRC08	8701	ATP6	Missense	No
CRC07	8705	ATP6	Missense	Yes
CRC08	9299	CO3	Synonymous	Yes
CRC08	9540	CO3	Synonymous	Yes
CRC12	9698	CO3	Synonymous	No
CRC08	9941	CO3	Synonymous	Yes
CRC12	10550	ND4L	Synonymous	Yes
CRC07	10704	ND4L	Missense	Yes
CRC12	11299	ND4	Synonymous	No
CRC12	11467	ND4	Synonymous	No
CRC07	11719	ND4	Synonymous	Yes
CRC08				Yes
CRC12				Yes
CRC12	12308	TL2	Non-coding	Yes
CRC07	12705	ND5	Synonymous	No
CRC08	12705	ND5	Synonymous	Yes
CRC08	12727	ND5	Synonymous	No

CRC08	13368	ND5	Synonymous	Yes
CRC07	13966	ND5	Missense	Yes
CRC07	13993	ND5	-	Yes
CRC12	14167	ND6	Synonymous	No
CRC12	14798	CYB	Missense	Yes
CRC08	15059	CYB	Stop gained	Yes
CRC07	15149	CYB	Missense	Yes
CRC01	15326	CYB	Missense	No
CRC07				Yes
CRC12				No
CRC08	15758	CYB	Missense	Yes
CRC07	15804	CYB	Missense	Yes
CRC08	15928	TT	Non-coding	Yes
CRC12	16192	CR	Intergenic	No
CRC12	16224	CR	Intergenic	Yes
CRC12	16311	CR	Intergenic	No
CRC07	16519	CR	Intergenic	Yes
CRC12				Yes

Table S5. Pairwise mtDNA differentiation among locations. Permutation p-values of the pairwise AMOVA calculation for the Nei's genetic distances calculated with the VAF values for different location groups per tissue. CRC01 tests were all non-significant.

CRC07	ND	NP	TD	TM
NP	0.692			
TD	0.000***	0.000***		
TM	0.034*	0.063	0.029*	
TP	0.956	0.801	0.000***	0.043*

CRC08	ND	NP	TC	TD
NP	0.328			
TC	0.346	0.000***		
TD	0.277	0.000***	0.000***	
TP	0.068	0.000***	0.000***	0.915

CRC12	ND	NP	TD	TM
NP	0.396			
TD	0.463	0.258		
TM	0.855	0.146	0.345	
TP	0.915	0.316	0.010**	0.883

^{NS} non-significant; * p-value ≤ 0.05, ** p-value ≤ 0.01, *** p-value ≤ 0.001

Table S6. Pairwise differentiation on type per tissue. P-values of the pairwise AMOVA calculation for the Nei's genetic distances were calculated with the VAF values for different groups of cell types per tissue.

CRC07	NNS	NS2	TNS		
NS2	0.043*				
TNS	0.001***	0.022*			
TS2	0.000***	0.000***	0.073		

CRC08	NS1	NNS	NS2	TS1	TNS
NNS	0.051				
NS2	0.504	0.219			
TS1	0.001***	0.691	0.869		
TNS	0.006**	1.000	0.929	0.508	
TS2	0.120	0.022*	0.500	0.049*	0.022*

CRC12	NS1	NNS	NS2	TNS
NNS	0.271			
NS2	0.190	0.814		
TNS	0.990	0.856	0.943	
TS2	0.222	0.127	0.037*	0.556

^{NS} non-significant; * p-value ≤ 0.05, ** p-value ≤ 0.01, *** p-value ≤ 0.001

Table S7. Single-cell samples. Cell type, geographical location, and number sampled for each patient.

Patient	Cell Type	Geographical location	Number of cells
CRC01	NS1	Mucosa, duodenum	2
	NS1	Spleen	2
	NNS	Adrenal gland (left)	1
	NNS	Large bowel	7
	NNS	Mucosa, duodenum	3
	NNS	Spleen	4
	NS2	Large bowel	4
	NS2	Mucosa, duodenum	9
	NS2	Spleen	4
	TNS	Large bowel	10
	Total		46
CRC07	NNS	Large bowel distal	14
	NNS	Large bowel proximal	12
	NS2	Large bowel distal	9
	NS2	Large bowel proximal	19
	TNS	Large bowel distal	12
	TNS	Large bowel middle	5
	TNS	Large bowel proximal	5
	TS2	Large bowel distal	15
	TS2	Large bowel middle	5
	TS2	Large bowel proximal	9
	Total		105
CRC08	NS1	Large bowel proximal	3
	NNS	Large bowel proximal	8
	NS2	Large bowel distal	1
	TS1	Large bowel central	8
	TS1	Large bowel proximal	14
	TNS	Large bowel central	8
	TNS	Large bowel distal	5
	TS2	Large bowel distal	5
	Total		52
CRC12	NS1	Large bowel distal	5
	NS1	Large bowel proximal	6
	NNS	Large bowel distal	5
	NNS	Large bowel proximal	5
	NS2	Large bowel distal	5
	NS2	Large bowel proximal	5
	TNS	Large bowel distal	12
	TNS	Large bowel middle	3
	TNS	Large bowel proximal	6
	TS2	Large bowel distal	2
	TS2	Large bowel middle	4
	TS2	Large bowel proximal	7
	Total		65

Figure S1. Coverage heterogeneity along the mitochondrial genome. The figure shows the average number of reads along the mtDNA sequence for each individual. Coverage for positions 1-4000 and 12001-16569 was calculated from the reads aligned to the shifted rCRS reference, while for positions 4001-12000, we calculated the coverage from the reads aligned to the rCRS reference.

Figure S2. Principal component analysis (PCA) for normal and tumor cells. PCA for individuals CRC01 (A), CRC07 (B), CRC08 (C) and CRC12 (D). Colors correspond to normal (blue) and tumor (red) cells. Ellipses represent a Normal distribution with a probability of 95% for the respective color group.

Figure S3. Principal component analysis (PCA) considering locations. PCA for individuals CRC07 (A and B), CRC08 (C and D), and CRC12 (E and F). Ellipses represent a Normal distribution with a probability of 95% for the respective color group. Left panels (A, C, and E) show only normal single-cells, and the right panels (B, D, and F) only tumor single-cells.

Figure S4. Principal component analysis (PCA) considering cell type. PCA for individuals CRC07 (A and B), CRC08 (C and D), and CRC12 (E and F). Colors according to cell type. Ellipses represent a Normal distribution with a probability of 95% for the respective color group. Left panels (A, C, and E) show only normal single-cells, and the right panels (B, D, and F) show only tumor single-cells.